Drug intelligence / Profile preview

remifentanil + lidocaine

Development stage
Phase 4
Lead developer
GSK
Modality
Small Molecules
Administration
Intravenous
01

Overview

Remifentanil + lidocaine is a combination of two pharmaceutical agents commonly used in anesthesia and perioperative pain management. Remifentanil is an ultra-short-acting synthetic opioid analgesic that acts as a potent agonist at the µ-opioid receptor, providing rapid-onset and short-duration analgesia. It is primarily used for induction and maintenance of general anesthesia, conscious sedation, and postoperative pain control[1][4][6]. Lidocaine is a widely used local anesthetic with additional properties including suppression of cough reflexes, analgesia, anti-hyperalgesia, and anti-inflammatory effects[5]. When administered together intravenously during surgical procedures or intubation/extubation events, lidocaine can reduce the required dose of remifentanil to suppress airway reflexes such as coughing while also decreasing the risk of respiratory depression associated with higher opioid doses[5]. This combination leverages both central (remifentanil) and peripheral (lidocaine) mechanisms to optimize patient comfort and safety during anesthesia.

02

Targets

MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on remifentanil + lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on remifentanil + lidocaine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call